This analysis was designed to characterize the population pharmacokinetics and pharmacodynamics of oral grepafloxacin (OPC-17,116) in patients with acute bacterial exacerbations of chronic bronchitis (ABECB). The study group included 76 patients (43 male, 33 female) between 23 and 81 years of age, who were part of a multicentre, randomized, double-blind, dose-response study. Patients were randomly assigned to receive oral regimens of grepafloxacin, 200, 400 or 600 mg, each administered once daily for 14 days. Plasma samples for drug assay (typically eight per subject; four samples on either day 3, 4 or 5, plus troughs on other clinic visit days), were obtained during treatment. Population pharmacokinetic analysis was accomplished using iterative two-stage analysis. Cultures and quantitative Gram stains from serial 24 h collections of sputum were used to determine the time (in days) taken to eradicate each bacterial strain. Population pharmacodynamic analysis was performed for three measures of antibacterial response: probability of bacteriological cure, probability of clinical cure, and time to eradication. Grepafloxacin plasma concentration profiles were best fitted by a pharmacokinetic model with first-order absorption following a lag time between administration of the dose and onset of systemic absorption. All three measures of response were strongly related to the 24 h AUIC (AUC/MIC). At an AUIC of <75, the percent probability of clinical cure was 71%; at an AUIC of 75-175, it was 80% (P < 0.05) and at an AUIC of >175, it was 98% (P < 0.01). In conclusion, antibacterial response for grepafloxacin in ABECB patients was highly related to AUIC; values of <75 appear inadequate and values of >175 were optimal.
Introduction
Achievement of an optimal relationship between the pharmacokinetics of fluoroquinolone antibiotics and the MIC of the infecting organism in the same patient, is predictive of eradication of the invading organism. [1] [2] [3] [4] [5] [6] Studies have advanced these principles in patients with nosocomial lower respiratory tract infections (LRTI). In a study of 73 LRTI patients given intravenous ciprofloxacin, the optimal area under the curve (AUC) to MIC ratio (AUC/MIC, or AUIC) was 125, which approximates 80% of the AUC above the MIC at dosing intervals of every 8-12 h. 1, 7 When the AUIC was 125, microbiological and clinical cure was achieved in significantly more of these patients. Ciprofloxacin displayed concentration-dependent bacterial killing in these patients. Bacterial eradication was significantly faster when the AUIC was 250 than when it was between 125 and 250. 1, 2 For patients with nosocomial LRTI having an AUIC below the threshold of 125, the microbiological failure rate approached 70%. 1, 6 Factors that alter the AUIC in individual patients can explain different outcomes in clinical trial patients. In the early phases of clinical antibiotic development, studies of the AUIC of patient populations given a range of doses can assist in the determination of an optimal dosage for patients with known infecting pathogens. Studies in LRTI patients demonstrate that variability in the clinical and microbiological response can be the consequence of pronounced inter-patient differences in pharmacokinetics. The primary determinant of variability in pharmaco-kinetics is typically renal function as a determinant of AUC and MIC, as it varies between organisms, even within the same bacterial species.
The AUIC-versus-outcome principles developed for ciprofloxacin should apply to the new fluoroquinolone antibiotic grepafloxacin (OPC-17,116). However, there are some factors unique to this compound that should be studied. Unlike most other antibiotics of this class, grepafloxacin is not excreted renally to any significant degree. Thus inter-and intra-patient variability in AUC may be less than or more than that for antibiotics like ofloxacin, which is excreted almost entirely by the renal route, 8 or ciprofloxacin, which is excreted by both renal and hepatic pathways. 8 Grepafloxacin is not being developed as a parenteral formulation, thus the antibiotic will have limited use in the nosocomial LRTI population. Its lack of activity against Pseudomonas spp. makes it more suited to the treatment of out-patient respiratory tract infections. We tested the AUIC principles of this new fluoroquinolone in patients with acute bacterial exacerbations of chronic bronchitis (ABECB), a condition previously shown to be a highly suitable model for studies of AUIC and bacterial eradication. 9, 10 In these patients, serial sputum specimens are readily obtainable, bacterial pathogens are present in most patients and the patients are sufficiently ambulatory to allow frequent blood sampling to determine their pharmacokinetic parameters. There has been little study of serial cultures and frequent blood samples in this population, so the impact of the disease on either pharmacokinetics or pharmacodynamics was unknown. The opinion that cultures are of little value in ABECB 9, 11 did not discourage this exercise; rather, this study seemed a good opportunity to determine if there was a relationship between organism eradication and the outcome of ABECB.
Patients and methods

Patient selection and randomization
Data were obtained during three prospective clinical trials of grepafloxacin for ABECB. Frequent sputum and blood samples were taken from all of these patients, to provide the data required for analysing the relationship between grepafloxacin pharmacokinetics and pharmacodynamics. Patients were older than 18 years, with a diagnosis of chronic bronchial disease, including but not limited to chronic bronchitis, chronic bronchial asthma, asthmatic bronchitis or bronchiectasis. Superimposed on this underlying disease, each enrolled patient had acute bacterial bronchial infection characterized by all of the following: (i) an increase in bronchopulmonary symptoms, (ii) an increase in inflammatory neutrophils in sputum and (iii) a sputum Gram stain analysis indicating the absence of contaminating oropharyngeal squamous cells and significant numbers of morphologically distinct bacteria.
Patients were excluded if there was a history of allergy to either -lactams or fluoroquinolones, if they required hospitalization or parenteral therapy, or if the chest radiograph indicated the presence of a pneumonia. Patients were also excluded if they had evidence of gastrointestinal disease or were taking either oral antacids or sucralfate, which could interfere with the absorption of oral medications 8 or if they had evidence of hepatic disease, renal insufficiency (serum creatinine 132.6 mol/L (1.5 mg/dL)), or they were receiving warfarin or fenbufen.
Study design and sampling procedures
In all three protocols, patients were randomized to receive once-daily oral doses of either 200, 400 or 600 mg grepafloxacin for 14 days. Study drug formulations were grepafloxacin 200 mg or placebo tablets. Patients were treated on an out-patient basis for 14 days with scheduled clinic visits on day 1; day 3, 4, or 5; day 8; day 10, 11 or 12; and day 14. On the days on which a clinic visit was scheduled, the patient was instructed to withhold the dose for that day and to bring all remaining study drug to clinic. The dose for that day was taken, under observation, at the prescribed time.
On clinic days there was an assessment of the nature and quality of bronchopulmonary signs and symptoms, and vital signs. Blood was collected for haematology and serum chemistries and determination of trough grepafloxacin concentrations. In any patients taking concomitant theophylline, a theophylline plasma concentration was also determined.
To describe the pharmacokinetics of grepafloxacin, it was necessary to obtain plasma samples at appropriate time points. In addition to the plasma trough samples obtained at clinic visits, four serum samples were obtained on either day 3, 4 or 5. These were obtained at pre-dose, 1 and 2 h after grepafloxacin administration, and a sample at least 1 h after the third sample but within 12 h after the dose. In total, each patient typically had eight samples obtained at 0, 72, 73, 74, 77, 168, 240 and 336 h. The times for these samples were based on optimal sampling theory [12] [13] [14] applied to previous data obtained in normal volunteers. 15, 16 Sputum was collected by the patients over the 24 h before their clinic visits. Volume was measured, and an aliquot was analysed for cell numbers, cell types, and culture to identify organisms. 17, 18 If a respiratory pathogen or predominant organism was isolated from a sample, bacterial susceptibility to grepafloxacin, as an MIC, was determined. From daily measurements of these specimens, we determined the time taken to eradicate bacteria from pulmonary excretions, bacterial response, inflammatory response and clinical response. Additional measures of disease resolution were made using the sputum neutrophil levels, and clinical data including frequent evaluations of bronchopulmonary symptoms.
Drug assay
Plasma samples were analysed for grepafloxacin by HPLC. In this method, grepafloxacin and the added internal standard, OPC-17,203, were extracted from plasma using a liquid-liquid extraction. This extract was then subjected to reversed phase HPLC, on a 5 m ODS column. Grepafloxacin and OPC-17,203 in the effluent were quantified using fluorescence detection. System calibration was accomplished for each batch of samples, by linear regression of the ratio of the peak height of grepafloxacin, to that of the added internal standard. Using 0.5 mL of plasma, the lower limit of quantification for grepafloxacin was 4.66 ng/mL (on the low curve) and 93.2 ng/mL (on the high curve). The method was linear up to at least 93.2 ng/mL and 2796 ng/mL on the low and high curves, respectively. As an independent estimate of accuracy and precision, blinded quality control samples were assayed in each batch, together with calibration and study samples.
Pharmacometric modelling methods
A population pharmacokinetic model, which consists of a vector of mean parameter values, a p p lower triangular covariance matrix (p is the number of structural parameter values), and a model for the residual variance of the observations (i.e. plasma concentrations), was fitted to the plasma concentration-time data. All grepafloxacin data in each subject were co-modelled. This included the trough plasma samples obtained from all clinic visits and the four plasma samples obtained on clinic days 3, 4 or 5. The individual and population parameter values were determined by the iterative two-stage analysis (ref. 14 and G. Prévost, personal communication). Modules developed within the ADAPT II 12, 13 package were used to implement the iterative two-stage program. In addition, individual estimates for each subject (pharmacokinetic point estimates and asymptotic covariance matrices), were also generated during this process. Model discrimination was accomplished using the rule of parsimony and Akaike's information criterion 19 .
Final structural model
The structural model employed is depicted in Figure 1 . Drug is administered into an absorptive compartment, X(3) is the amount of drug in this compartment; F is the systemic bioavailability and, after a lag time (T lag ), grepafloxacin is absorbed (according to a first order rate constant, k a ) into a central compartment of apparent volume V c ; in this model, X(1)/V c is the plasma concentration. Drug in the central compartment equilibrates (Cl d is the distributional clearance) with drug in the peripheral compartment of apparent volume V p ; in the model, X(2) is the amount of drug in this compartment, and it is eliminated from the central compartment by a saturable process, defined as the intrinsic clearance (Cl i ) and the Michaelis constant (K M ). Because the doses were oral, the fitted volumes and clearances are dependent on F, which could not be estimated in a study of this design. Several other pharmacokinetic parameter values can be derived from the fitted parameters. For example, the oral volume of distribution at steady-state, cp and k pc are inter-compartmental transfer rate constants); and V max Cl i K M . This model was based on earlier single-and multiple-dose pharmacokinetic studies, in normal young adults. 15, 16 However, other models (e.g., one with linear clearance), were also considered.
Identification of factors predictive of grepafloxacin pharmacokinetics
An initial statistical screen of the effects of age, race, gender, weight, smoking history, alcohol usage, laboratory values, pulmonary diagnosis, dose, clinical study site, concomitant medications (e.g., theophylline) and active medical problems, upon the pharmacokinetics of grepafloxacin, was performed by classification and regression tree (CART) analysis, a procedure which uses recursive partitioning, multiple stepwise linear regression 20, 21 and the Kruskal-Wallis non-parametric one-way analysis of variance. 20 Those factors significantly associated with pharmacokinetic parameter values were incorporated into the population pharmacokinetic model and were tested by Akaike's information criterion.
Differences in variance were evaluated using the variance ratio (the F-test). Graphical depictions of differences between groups were accomplished using notch plots. 22 Referring to Figure 5 as an example of a notch plot, the horizontal line, at the narrowest portion of the plot, is the median of the data (the 50th percentile); the notch (the indented region) indicates the 95% confidence interval about the 'true' value of the median; the vertical dimensions of the box delimit the inter-quartile range (the 25th-75th percentiles), i.e., the upper and lower horizontal lines are the 25th and 75th percentiles, respectively; the bars extending out from the box show the approximate 99% range for the observed data; outliers (determined by the graphing module) are indicated as an asterisk; distant outliers are indicated as an open circle. The outliers were not excluded from any of the analyses. 
Modelling the pharmacodynamics of response
Three measures of antimicrobial response were modelled: probability of a bacteriological cure, probability of a clinical cure, and time (in days) taken to eradicate bacteria from pulmonary secretions. Probability of cure was initially modelled using both multifactorial and stepwise logistic regression 23 and CART. Then certain relationships were modelled using a Hill-type pharmacodynamic model. 1, 3 The time taken to eradicate bacteria was modelled using proportional hazards regression. 24 The independent variables evaluated were the same for all three measures of antibacterial response. These included the bacterial species and MIC, and the patients' age, pulmonary diagnosis (e.g., chronic bronchitis, chronic bronchial asthma, bronchiectasis, etc.), other active medical problems, concomitant drugs, laboratory values and the clinical site at which they were treated.
The conventionally reported MIC is biased upwards; for example, a reported MIC of 1.0 mg/L usually means that there was growth at 0.5 mg/L and none at 1.0 mg/L; thus, the 'true' MIC is between these two values. For this reason, the MIC used in the statistical modelling was transformed to the 'MIC midpoint' (MIC mp ). This was computed as the midpoint between the reported MIC and the next lower value in the dilution series. Thus, for an MIC of 1.0, the MIC mp was 0.75, the midpoint between 0.5 and 1.0 mg/L. It is easy to inter-convert MIC mp and MIC values: MIC mp MIC 3/4.
The independent variables also included the following measures of drug exposure: dose (as mg/day), the 24 h area under the plasma concentration-time curve (AUC), the AUIC mp (AUC/MIC mp , AUIC 0.75 AUIC mp ), the peak plasma concentration achieved on day 5 (peak), the ratio of peak/MIC mp , the trough following the fifth dose (trough), the trough/MIC mp and the percent of time that plasma concentrations were above the MIC mp (during the fifth dose interval).
The plasma concentration profile for the fifth dose interval (approximately 96-120 h) was intensively reconstructed through simulation as demonstrated in Figure 2 . The 'near steady-state' peak, trough and percent of time above the MIC were based on these data. The 24 h AUC, for each bacterial isolate, was determined by numerically integrating the plasma concentration profiles, from the beginning of treatment until DTE (the number of days of treatment until eradication of that strain from pulmonary secretions, or until treatment was ended (whichever occurred first), and then dividing that value by the number of days elapsed. Thus, the 24 h AUC, averaged over that period (0 to DTE), was obtained.
This computation of AUC and AUIC is depicted graphically in Figure 2 . A pharmacokinetic model (smooth curve) was fitted to the observations (closed circles) and the AUC 0 DTE (shaded area) was obtained by numeric integration. The 24 h AUC and the AUIC mp , which were used as potential covariates of response, were computed as: To perform logistic regression for a continuous potential covariate (such as AUIC), the range of values was divided into cells (using a geometric progression for endpoints), with reasonable numbers of cases in each. Then, in the course of analysis, adjacent cells that did not differ significantly (in probability of cure, for example), were sequentially collapsed, until only groups that were different remained.
To perform CART, the continuous independent variables did not need to be empirically divided into cells. The CART procedure determined the optimal breakpoints for the continuous independent variables. The minimum number of cases for each side of a split (breakpoint that defines the cells), was constrained to four. Although the two methods are largely redundant, to determine the parameters which were significantly associated with likelihood of cure and the optimal breakpoints, CART and logistic regression were performed in parallel. Performing both, and investigating reasons for any differences, improved the probability of deriving the optimal model. Both logistic regression and CART are relatively nonparametric methods, which we use mainly as screening techniques; during the screening process, care is taken to minimize the imposition of a rigid model on the relationship between covariates and responses. After the significant covariates had been identified, a parametric model, a Hill-type equation, was considered. For a single continuous, independent variable, the Hill-type model was of the following form:
(P max P 0 ) X H percent probability of cure P 0 , X H 50% X H in which P max is the asymptotic maximum response rate, P 0 is the asymptotic baseline response rate (the probability of cure as X approaches 0; a value that is not necessarily 0, because a proportion of patients diagnosed as ABECB would recover without drug treatment). X is the measure of drug exposure (AUIC, for example) and X 50% is the drug exposure at which percent probability of cure is (P 0 P max )/2; H is Hill's constant (a variable that reflects degree of sigmoidicity). This model was implemented by coding each cure as response 1, and each failure as response 0 and then fitting the above model, using a maximum likelihood objective function.
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Integration of pharmacokinetics and pharmacodynamics to determine optimal dosage regimens
For all 76 patients, the fitted individual pharmacokinetic models were used to predict the plasma concentration profiles (including 24 h AUC values) that would have been predicted, for oral grepafloxacin regimens of 300, 400 and 600 mg/65 kg per day. The AUCs were also converted into the resulting 24 h AUIC values, that would have been achieved if the MIC were 0.125, 0.25 and 0.5 mg/mL. Thus each of the 76 patients had nine AUIC values predicted (three MICs and three regimens).
The pharmacodynamic analyses provided models relating drug exposure and other covariates to probability of clinical and bacteriological cure and to time to eradication of bacteria from sputum. These models were used to predict the number of patients that would have been cured on each regimen and at each MIC value and the number of days of therapy that sputum would have remained culturepositive. These data enabled a recommendation of the optimal dose and duration of therapy, for treatment of ABECB, in this target population.
Results
Demographics and distribution of assigned doses
Seventy-six patients (43 males, 33 females) were randomized to once-daily, oral grepafloxacin dosage regimens (27 patients were given 200 mg, 24 patients given 400 mg and 25 patients given 600 mg). The median (range) weight was 74 (41-129) kg and age was 63 (23-81) years old. All patients except one were Caucasian. A total of 617 grepafloxacin plasma concentrations were obtained in these 76 patients; the median (and mean) was eight, with a range of two to 12 samples per subject.
Bias and precision of the fitted model
The pharmacokinetic model and final parameter values fi t the data very well. This can be seen in Figure 3 , which depicts the observed plasma concentrations (y-axis) plotted against fitted values (x-axis) for all of the observations in the 76 patients. By weighted, linear regression (a maximum likelihood objective function), the line of best fit through these data did not differ from the line of identity (diagonal). The fitted parameter values, for the residual variance model, were 0.11 and 5.0 mg/mL, for u 1 and u 2 , respectively. This residual variance model suggests that, at a plasma concentration of 20 ng/mL, the standard deviation was approximately 7.3 ng/mL, and at 1000 ng/mL, was 117 ng/mL. Table I summarizes the fitted pharmacokinetic parameter values for all 76 patients. The AUC avg was computed by simulating the plasma concentration profiles that would be achieved by giving 600 mg/65 kg/day for 7 days. The AUC avg was obtained by numerically integrating the AUC (0 7 day) and dividing by 7, thus yielding the 24 h AUC, averaged over days 1-7. With increases in assigned dose, the increase in actual (fitted) AUC values was disproportionately high (data not shown). This phenomenon was probably the consequence of saturable elimination, not differences between groups, in clearance and/or bioavailability. The notch plot in Figure  4 illustrates the lack of difference in pharmacokinetics between the three dosing groups. For patients that had been randomized to receive 200, 400 and 600 mg per day, this notch plot shows the equivalence of distributions of AUC avg . The figure demonstrates that, if all subjects were given the same weight-normalized dose, the median AUC values would have been similar between groups.
Fitted pharmacokinetic parameter values
Table I also summarizes the pharmacokinetic parameter values by age group: it includes a summary of pharmacokinetic parameter values in the 19 patients below 50 years of age, the 12 patients 50-59 years old, the 24 patients 60-69 years old and the 21 patients at least 70 years of age. None of these groups differed in concentrations achieved (or in AUC avg ). In fact, neither age, gender, dose, nor study site (race was not assessed because 75/76 patients were Caucasian) were significant predictors of the pharmacokinetics of grepafloxacin.
These trends are illustrated in Figure 5 , which is a notch plot that shows the dispersion of computed values for AUC avg , for six study groups, given 600 mg/65 kg/day. Study group 1 comprised 20 young adults, 15, 16 ; group 2, 17 elderly volunteers; 23 group 3, 19 ABECB patients less than 50 years old; group 4, 12 ABECB patients between 50 and 59 years old; group 5, 24 ABECB patients between 60 and 69 years old; group 6, 21 ABECB patients at least 70 years of age. There were no differences, between groups, in median values of AUC avg ; the inter-subject variance was greater in the ABECB patients. Table II presents a summary of the exposure covariates developed out of the integration of the pharmacokinetics with the MIC. For peak and trough, the number of cases (n) is equal to the number of patients (76). These values were obtained from the 'intensively reconstructed' (simulated) fifth dose interval. For AUC (AUC 0 DTE /DTE) and the measures related to MIC mp , n is equal to the number of bacterial strains isolated (119).
Pharmacodynamic response
As can be appreciated from the data in Tables I and II , there was substantive inter-patient variance in AUC (e.g., coefficient of variation in percent (CV%) 92), peak (CV% 65) and trough (CV% 86) concentrations and that the probability of clinical cure was higher with a 600 mg dose than with a 200 mg dose (P 0.005). When response was partitioned by bacterial species and AUIC mp (Table IV) , cell sizes were small, but it could be appreciated that Pseudomonas aeruginosa and Staphylococcus aureus had lower probabilities of both bacteriological and clinical cure. Most of the species differences in AUIC mp were a consequence of species differences in MIC mp (Table V) . For both microbiological and clinical cure, there was a decreasing probability of cure with increasing MIC mp (Table III) .
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Tables III and IV present activity measures that integrate the pharmacokinetics with the potency (e.g., MIC) of the drug. All of the factors tested (percent of time above the MIC mp , AUIC mp , peak/MIC mp and trough/ MIC mp ) covaried strongly and all exhibited a trend for increasing likelihood of cure with increasing activity. AUIC mp , as presented in Table III , was the 'best' (most predictive of outcome) of these variables. Figure 6 is a histogram showing the percent probability of clinical cure and failure as a function of the AUIC (not AUIC mp ; to convert AUIC to AUIC mp , multiply by 4/3.)
Multivariate analyses. Probability of cure and time to eradication are complex functions, usually dependent on a number of factors. To obtain an optimal assessment of the factors that affect antibacterial response, requires integration of the antibiotic dosage regimen and pharmacokinetics (to determine exposure profile), with the susceptibility of the bacteria to the drug (as reflected by MIC, for example). These and other factors should then be considered simultaneously, using the appropriate multivariate methods of analysis. When multivariate, stepwise logistic regression and a recursive partitioning procedure (CART) were used to determine covariates to the probability of bacteriological and of clinical cure, both methods found that AUIC mp was the most important determinant of response. For probability of bacteriological cure, there was a single breakpoint at an AUIC mp of 92 (an AUIC of 69). Below this limit, 20/35 (57%) strains were eradicated, and above an AUIC mp of 92, 75/83 strains (90%) were eradicated. For probability of clinical cure, two breakpoints, at an AUIC mp of 92 and at a value of 230 (an AUIC of 173), were identified. Below an AUIC mp of 92, 20/28 evaluable strains (71%) were associated with clinical cure; at an AUIC mp between 92 and 230, 12/15 strains (80%) were cured; and at an AUIC mp greater than 230, 45/46 strains (98%) were associated with a clinical cure.
With AUIC mp in the model, none of the other drug exposure measures (e.g., dose, peak, peak/MIC, AUC, time above the MIC, etc.) nor MIC, infection site, etc., provided any additional information. One possible exception is bacterial species. As can be seen in Table V , there is a suggestion of some species-specific sensitivity, not 'explained' by AUIC. However, the cells in this table each contain relatively small numbers of bacteria. Examination of Table V reveals the possibility that P. aeruginosa might be significantly less sensitive and that Streptococcus pneumoniae might be more sensitive than might be predicted by the respective AUIC mp . In our previous work, in patients with nosocomial lower respiratory tract infections receiving a different fluoroquinolone, no species-specific differences in response versus AUIC, were noted. 1 It is possible that this could be an effect of ABECB, or Pseudomonas could be a marker of more severe pulmonary involvement, and thus an indirect measure of disease response. Given the continuous relationship between probability of cure and AUIC (see Tables IV and V 55, 88 8.9 AUIC mp 8.9 in which 91 (P max ) is the asymptotic maximum response rate, 55 (P 0 ) is the asymptotic baseline response rate (the probability of cure without drug treatment), 88 (AUIC 50% ) is the AUIC mp at which percent probability of cure is (P 0 P max )/2, and 8. in which 98 is P max , 69 is P 0 , 128 is AUIC 50% , and 2.0 is Hill's constant. The very large baseline response (P 0 ) is notable, and is probably a function of the disease.
The last pharmacodynamic measure that we modelled is the time (in days) required to eradicate bacteria from the sputum. Proportional hazards analysis was performed on 117 evaluable strains in 76 patients. Again, of all of the potential covariates, AUIC was the most informative and, once AUIC was in the model, no other factor was significant. Figure 9 shows the Kaplan-Meier plots for the percent of strains remaining culture positive (vertical axis) plotted against days of therapy (horizontal axis), with each symbol marking a different AUIC range. After consolidating the AUIC regions that did not differ, three curves remained ( Figure 9 ). At an AUIC of 75 (n 36), the median time (in days) to eradication (DTE 50% ) was 2.5 days and the time to eradication of 75% of strains (DTE 75% ), was infinity (at an AUIC of 75, the predicted proportion of strains eradicated was 55%; even extrapolating beyond the study period, more than 25% of strains would be predicted to remain culture-positive). At an AUIC of 75-190 and at an AUIC of 190, the DTE 50% was 0.5 days and the DTE 75% was 1.5 days. The first curve differed from the second two overall (P 0.001). The second two curves did not differ overall (0.05 P 0.1), but did differ over the period of 3.5-8.5 days (P 0.05). Table VI shows the results of the simulations that provided AUC and AUIC values. For an MIC of 0.125 mg/mL, 300 mg/65 kg/day would be predicted to yield 25 patients (33%) with an AUIC between 37.5 and 75; 400 mg/65 kg/day would yield six patients (8%) with an AUIC between 37.5 and 75; and, at 600 mg/65 kg/day, all patients would be predicted to achieve an AUIC of 75. For an MIC of 0.25 mg/mL, 300 mg/65 kg/day would yield 62 patients (82%) with an AUIC of 75; 400 mg/65 kg/day would yield 44 patients (58%) with an AUIC of 75; and 600 mg/65 kg/day would be predicted to yield 10 patients (13%) with an AUIC of 75. For an MIC of 0.5 mg/mL, even 600 mg/65 kg/day would be predicted to yield 50 patients (66%) with an AUIC of 75. Figure 10 depicts the predicted rates of eradication for infections by bacteria with MICs of 0.5, 0.25 and 0.125 mg/L, for ABECB patients given 300, 400 and 600 mg/65 kg/day. Figure 11 shows the same information for doses of 600, 400 and 300 mg/65 kg/day, for the three MICs (0.125, 0.25 and 0.5 mg/L). A subset of the results contained in Figures 10 and 11 is summarized in Table VI . For all nine MIC-dose combinations, the predicted percentage of patients predicted to remain culture positive after 3, 5, 7 and 10 days of therapy is tabulated.
Determination of optimal dose and duration
Discussion
Overall, grepafloxacin performed well in these ABECB patients, from both a pharmacokinetic and a clinical perspective. Considering that this agent is primarily excreted as metabolites, the pharmacokinetics were reasonable for a diverse group of patients with a wide range of age and underlying diseases. Although the patient population contained both smokers and non-smokers, the drug displayed reasonably predictable AUCs. Grepafloxacin bioavailability is not known, yet the serum profiles varied little between patients. On average the serum concentrations exceeded the MIC for at least a part of the dosing interval in virtually all ABECB patients. There were problem MIC values for this agent, as is typical of previously studied fluoroquinolones, and indeed, other classes of antibiotic as well.
Population pharmacokinetics
The population pharmacokinetic model fit the data very well (overall r 2 0.986). Inter-patient variance in pharmacokinetic parameters and AUC values were substantive. AUCs were not adjusted for body weight, which may remove some of the variability. comial pneumonia, failure to eradicate the organism leads to continued infection symptoms, organism resistance and clinical failure. 1, 2, 4, [25] [26] [27] In nosocomial pneumonia, organism eradication is a prerequisite to cure. This may or may not apply to patients with ABECB, where it appears that disease resolution is more common even when the antibiotic would not be active against the isolated organism. 10, 28 Based on studies in nosocomial pneumonia, 25 resistance selection is also predicted in situations where ABECB patients do not have bacterial eradication. Even selected resistance in this patient population may not be associated with clinical failure, but the selection of resistance could result in a slower resolution of disease, and potentially cross-transmission of resistant organisms to other patients. 
